BIOGEN INC
BIIBNASDAQ🏆 #345 by market capBiotech
$204.00▼ $3.10 (−1.52%)
Live1h—
24h▼ 1.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$30.14B
Mid Cap
📈Revenue Growth (YoY)
+0.3%
Slowing
📊Gross Margin
74.0%
High
💵FCF Margin
25.3%
Strong
⚖️P/S Ratio
3.1x
Fair
Otter Score
45
Weak
No chart data available for BIIB.
Trading Snapshot
- Day Range
- $202.22 – $204.96
- 52-Week Range
- $127.00 – $219.72
- Volume
- $3.91B
- Avg Volume
- $4.29B
- Shares Outstanding
- 147.8M
- Next Earnings
- Sep 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $10.00B
- Last Q Revenue
- $2.73B
- P/E Ratio
- 36.8
- P/S Ratio
- 3.1x
- EPS (TTM)
- $5.65
- Dividend Yield
- —
Why Investors Own BIIB
- ✓High-growth profile — revenue up +57.2% YoY with expanding Biotech exposure.
- ✓Healthy economics — 66% gross margin and 8% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$10.00B▲ +57.7% YoY
Gross Margin (TTM)
66.3%▲ +3.0% YoY
Operating Income (TTM)
$1.97B▲ +57.7% YoY
Free Cash Flow (TTM)
$820M▲ +57.7% YoY
About BIOGEN INC
A company profile for BIOGEN INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$263.23
▲ +29.0% Upside
High Target$313.84
Low Target$226.15
Based on 37 analysts
Latest News & Updates
🚀
Barron’s·2h ago
BIOGEN INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift BIIB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
BIOGEN INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.